PHARMATHEN
The Pharmathen Group saw a 16% increase in turnover last year to over €317 million, and a €15.8 million increase in EBITDA to €68.31 million from 2022 to 2023, mostly as a result of higher sales volume and improved gross profit margin.
23/07/24 • 08:45
Pharmathen announced today the acquisition of CBL Patras ("CBL"), a high-tech vertically integrated peptide production company approved by the US Food and Drug Administration (FDA).
06/11/23 • 17:37